logo-loader
viewRoku Inc

Rovio Entertainment, Angry Birds, Roku and Zynerba Pharmaceuticals - PRE-MARKET

We take a look at what's likely to move the needle in New York today

Rovio Entertainment, Angry Birds, Roku and Zynerba Pharmaceuticals Inc  - PRE-MARKET
Rovio Entertainment makes Angry Birds

After the record finish, US futures show a mixed start to the day's proceedings on Wall Street.

Likely to be of big interest is Rovio Entertainment, which makes the game Angry Birds, which priced its IPO (initial public offering) and has now started trading in Helsinki and will begin changing hands on NASDAQ Helsinki's official list on October 3.

It priced shares at €11.50 (US$13.50) a share, valuing the Finnish tech firm at over US$1bn, and on debut,  shares added over 5%.

Some commentators suggested that given that the IPO was multiple times oversubscribed, the share rise at launch was not so overtly large.

 

Speaking  of floats, yesterday Roku (NASDAQ: ROKU) made its debut in New York and the streaming service got off to a flying start.

 

The video-streaming firm backed by Fox, saw shares jump up to 78% when it made its debut in New York after it raised US$219mln in an initial public offering that was priced towards the upper end of what it had expected.

The stock is likely to again be closely monitored today by traders.

Shares in Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) added 3.81% to US$9.80 in after hours deals after it reported positive top-line results for its phase 2 study of its candidate to treat children with Fragile X syndrome.

Fragile X Syndrome is a genetic condition and is the most common known cause of inherited learning disabilities.

The cannabinoid transdermal gel “successfully met its primary endpoint” on the Anxiety, Depression and Mood Scale (ADAMS) and showed “clinically meaningful improvements” in behaviour, according to a statement from the firm.

Quick facts: Roku Inc

Price: 130.38 USD

NASDAQ:ROKU
Market: NASDAQ
Market Cap: $15.4 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Revenue guidance from OptiBiotix as it eyes NASDAQ listing

OptiBiotix Health (LON:OPTI) provides a commercial progress update, explaining why in their financials some items are separated. CEO Stephen O'Hara tells Proactive London what's behind his thinking adding that Optibiotix hopes to reach profitability in 2020. News here too on Sweetbiotix and...

13 hours, 45 minutes ago

2 min read